Original Research

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients

Mark Kowalski, Joycelyn Entwistle, Jeannick Cizeau, et al

Drug Design, Development and Therapy 2010, 4:313-320

Published Date: 15 November 2010